Gazyvaro Recommended for Active Lupus in Europe
The European Medicines Agency's CHMP has recommended extending Roche's Gazyvaro to adults with autoantibody-positive active systemic lupus erythematosus.
Updated on Nov. 17, 2026 in Arthritis

Live Poll
Do you trust doctors to recommend the newest treatments for serious illnesses?
The Committee for Medicinal Products for Human Use (CHMP) recommended extending the marketing authorization of Roche's Gazyvaro (obinutuzumab) as an add-on treatment for adults with autoantibody-positive active systemic lupus erythematosus (SLE) whose disease remains active despite standard therapy. The European Commission will decide whether to extend the EU-wide authorization.
Why it matters
Some SLE patients continue to have active disease despite standard therapy, putting them at risk of permanent organ damage and cardiovascular disease. A positive regulatory recommendation could give these patients a new treatment option in Europe.
In the 303-patient ALLEGORY phase 3 trial, DORIS remission reached 33.8% with obinutuzumab versus 13.8% with placebo, and lupus low disease activity state reached 57.6% versus 25.0% over 52 weeks. Long-term safety and effects beyond the 104-week open-label extension are not described in the extraction.
The players
Roche
Roche is a Swiss multinational healthcare and diagnostics company that developed Gazyvaro (obinutuzumab) and sought the extension for lupus.
The details
Obinutuzumab, a humanized, glycoengineered type II anti-CD20 monoclonal antibody, binds CD20 on B cells and induces B-cell death, and the recommendation rests on the ALLEGORY trial, in which adults with active SLE received obinutuzumab or placebo alongside standard therapy for 52 weeks. The European Commission's decision will determine whether the EU-wide marketing authorization is extended.
Timeline
Obinutuzumab was first authorized in the EU in July 2014 for chronic lymphocytic leukemia and follicular lymphoma.
The CHMP recommendation was published on November 17, 2026.
Big Picture
This recommendation extends obinutuzumab's centralized EU authorization, first granted in July 2014 for blood cancers, into autoimmune disease. It shows the EU centralized procedure being used to add a new indication to an existing anti-CD20 antibody.
If approved, adults with autoantibody-positive active SLE who have not responded enough to standard therapy could gain access to an add-on treatment option. Actual availability will depend on national price and reimbursement decisions made by each member state.
The takeaway
Patients with lupus whose disease stays active on standard treatment may have a new option under consideration, but its availability will depend on the European Commission decision and national reimbursement policies. Talk with a rheumatologist about whether new therapies could fit your treatment plan.
What happens next
The European Commission will decide whether to extend the EU-wide marketing authorization for Gazyvaro in the indication.
Further reading
Explore more on Arthritis to see how autoimmune inflammatory conditions are treated and managed.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust doctors to recommend the newest treatments for serious illnesses?



